IGF-1 Research: Growth vs Longevity

Summary

IGF-1 mediates most of growth hormone's anabolic effects and is one of the most conserved longevity-regulating pathways across species. Human epidemiology shows a U-shaped relationship with mortality: both low and high IGF-1 associate with worse outcomes, which makes simple 'raise it' or 'lower it' framing wrong.

Last reviewed 2026-09-01

What it is

Insulin-like growth factor 1 is a 70–amino-acid peptide hormone produced mainly by the liver under GH stimulation, structurally similar to insulin and circulating almost entirely bound to IGF-binding proteins, principally IGFBP-3.

Originally called somatomedin C when identified in the 1950s as the mediator of GH's growth effects. Its central role in ageing emerged from C. elegans daf-2 mutant studies in the 1990s, where reduced insulin/IGF-1 signalling doubled lifespan.

Endogenous; hepatic production dominates circulating levels while local tissue production acts in paracrine fashion.

The insulin/IGF-1 signalling pathway is the most evolutionarily conserved lifespan modulator known, conserved from nematodes to mammals.

How it works

In plain terms

IGF-1 tells cells to grow and divide, and discourages them from breaking down and recycling their own components. That is useful for building tissue and less useful for long-term maintenance — hence the trade-off.

Technical detail

IGF-1 binds IGF-1R, a receptor tyrosine kinase, activating PI3K-Akt and Ras-MAPK signalling. Akt activation inhibits FOXO transcription factors, reducing expression of stress-resistance, antioxidant and autophagy genes, and activates mTORC1, promoting protein synthesis while suppressing autophagy. In model organisms, reduced signalling frees FOXO (DAF-16 in C. elegans) to upregulate maintenance programmes — the mechanistic basis of the longevity phenotype. Circulating IGF-1 is 99% bound to IGFBPs, so total measurements can obscure bioavailability.

Pathways involved

IGF-1R → PI3K-Akt → FOXO inhibition
Akt → mTORC1 → protein synthesis, autophagy suppression
Ras-MAPK proliferative signalling
IGFBP-3 and ALS ternary complex regulating bioavailability

Current research

Laboratory research

Pathway architecture is exceptionally well characterised across model systems.

Animal research

Reduced insulin/IGF-1 signalling extends lifespan in C. elegans, Drosophila and mice. IGF-1R heterozygous mice live longer, with sex-dependent effect size. Caloric restriction lowers IGF-1 in most species, though not consistently in humans without protein restriction.

Human research

Cohort studies show a U-shaped association: both the lowest and highest IGF-1 quintiles associate with higher all-cause mortality, with low IGF-1 linked to cardiovascular death and high IGF-1 to cancer incidence, particularly prostate, breast and colorectal. Centenarian studies have identified IGF-1R functional variants enriched in long-lived cohorts, notably among Ashkenazi Jewish centenarians. Human caloric restriction lowers IGF-1 mainly when protein intake falls.

Ongoing research

IGF-1 as a modifiable target remains contentious; most work is observational or mechanistic rather than interventional.

What is being investigated

U-shaped IGF-1 mortality association in cohorts
IGF-1R variants in long-lived human populations
Protein intake and dietary modulation of IGF-1
Cancer incidence associations across tissues
FOXO and autophagy signalling as maintenance programmes

These are research directions reported in the literature, not established effects or recommendations.

Risks, limitations and unknowns

Read this section before the rest

Higher IGF-1 associates with increased incidence of several cancers in cohort data
Lower IGF-1 associates with cardiovascular mortality and frailty — reduction is not automatically beneficial
Total IGF-1 measurements do not reflect bioavailability without IGFBP-3 context
Model organism lifespan findings have not been translated into any human intervention
Assay standardisation between laboratories remains imperfect

Evidence ratings

Laboratory studies

Strong

Pathway biology exceptionally well defined.

Animal studies

Strong

Lifespan extension with reduced signalling is highly reproducible.

Human observational

Moderate

Consistent U-shaped mortality association across cohorts.

Human interventional

None

No trial has tested IGF-1 modulation for longevity endpoints.

Verified peptide suppliers

References

[1]IGF-1 and mortality — cohort analyses — PubMed, 2010–present
[2]Insulin/IGF-1 signalling and longevity — PubMed, 1993–present
[3]IGF-1R variants in centenarians — PubMed, 2008–present
Reference links open searches and records on PubMed and ClinicalTrials.gov so that every statement above can be traced to primary literature.

Frequently asked questions

What is IGF-1?+

Insulin-like growth factor 1, a peptide hormone produced mainly by the liver under growth hormone stimulation, mediating most GH anabolic effects.

Is high IGF-1 good or bad?+

Neither uniformly. Cohort data shows a U-shaped mortality relationship — low levels associate with cardiovascular death, high levels with cancer incidence.

Why does reduced IGF-1 signalling extend lifespan in animals?+

Reduced Akt signalling releases FOXO transcription factors, which upregulate stress resistance, antioxidant defence and autophagy programmes.

Does protein intake affect IGF-1?+

Yes. In humans, IGF-1 reduction from caloric restriction depends largely on reduced protein intake rather than calories alone.

What is daf-2?+

The C. elegans insulin/IGF-1 receptor gene; partial loss-of-function mutations roughly double nematode lifespan, the founding finding of the field.

How is IGF-1 measured?+

As total serum IGF-1, ideally interpreted alongside IGFBP-3 and age-specific reference ranges, since 99% circulates protein-bound.

Should IGF-1 be lowered deliberately?+

No human trial supports that. Both ends of the distribution carry risk, and no intervention has been tested for longevity endpoints.

Is IGF-1 the same as insulin?+

No, though they are structurally related and their receptors share signalling machinery, which is why the pathway is called insulin/IGF-1 signalling.

Continue your research

Growth hormone research

Cellular health

Metabolic health